Literature DB >> 20583125

History of outcome measures for myasthenia gravis.

Ted M Burns1.   

Abstract

This review illustrates how measurements of clinical status in patients with myasthenia gravis have evolved from clinical descriptions and estimates of mortality rates to more sophisticated evaluative instruments, including numerical rating scales that measure strength, endurance, quality of life, and activities of daily living. The rationale and use of weighting and the importance of patient-reported outcomes are also discussed. The measurement of the steroid-sparing effect of an immunosuppressant is also reviewed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20583125     DOI： 10.1002/mus.21713

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  10 in total

1.  Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.

Authors:  Pei Chen; Huiyu Feng; Juan Deng; Yufei Luo; Li Qiu; Changyi Ou; Weibin Liu
Journal:  J Neurol       Date:  2015-10-29       Impact factor: 4.849

2.  Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.

Authors:  Alberto Raggi; Carlo Antozzi; Fulvio Baggi; Matilde Leonardi; Lorenzo Maggi; Renato Mantegazza
Journal:  Neurol Sci       Date:  2017-08-05       Impact factor: 3.307

Review 3.  History of Myasthenia Gravis Revisited.

Authors:  Feza Deymeer
Journal:  Noro Psikiyatr Ars       Date:  2020-11-07       Impact factor: 1.339

4.  Validation of the MG-DIS: a disability assessment for myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Silvia Schiavolin; Carlo Antozzi; Greta Brenna; Lorenzo Maggi; Renato Mantegazza
Journal:  J Neurol       Date:  2016-03-01       Impact factor: 4.849

Review 5.  PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis.

Authors:  Xunbo Xiong; Mingqing Xiang; Xianglin Cheng; Yi Huang
Journal:  Med Sci Monit       Date:  2015-08-30

6.  Preoperative high-dose steroid has long-term beneficial effects for myasthenia gravis.

Authors:  Syuichi Tetsuka; Ken-Ichi Fujimoto; Kunihiko Ikeguchi
Journal:  Neurol Res Int       Date:  2013-07-14

7.  Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.

Authors:  Yuriko Nagane; Hiroyuki Murai; Tomihiro Imai; Daisuke Yamamoto; Emiko Tsuda; Naoya Minami; Yasushi Suzuki; Tetsuya Kanai; Akiyuki Uzawa; Naoki Kawaguchi; Masayuki Masuda; Shingo Konno; Hidekazu Suzuki; Masashi Aoki; Kimiaki Utsugisawa
Journal:  BMJ Open       Date:  2017-02-23       Impact factor: 2.692

8.  Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p.

Authors:  Francesca Beretta; Yu-Fang Huang; Anna Rostedt Punga
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

Review 9.  Utilization of MG-ADL in myasthenia gravis clinical research and care.

Authors:  Srikanth Muppidi; Nicholas J Silvestri; Robin Tan; Kimberly Riggs; Trevor Leighton; Glenn A Phillips
Journal:  Muscle Nerve       Date:  2022-01-06       Impact factor: 3.852

10.  Determinants of quality of life in Brazilian patients with myasthenia gravis.

Authors:  Aline Mansueto Mourão; Rodrigo Santiago Gomez; Luiz Sergio Mageste Barbosa; Denise da Silva Freitas; Elizabeth Regina Comini-Frota; Arthur Kummer; Stella Maris Aguiar Lemos; Antonio Lucio Teixeira
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.